Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance

Diabetes Research and Clinical Practice

Volumn 74, Issue 3, 2006, Pages 233-241

  Jin, Juying ^a   Yu, Yerong ^a   Yu, Honglin ^a   Wang, Chun ^a   Zhang, Xiangxun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Beta cell function; Clamp study; IGT; Metabolic syndrome; Pioglitazone

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; PIOGLITAZONE; PROINSULIN; RECOMBINANT HUMAN INSULIN;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; METABOLIC SYNDROME X; PANCREAS ISLET BETA CELL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 33750017577     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.04.020     Document Type: Article

References (47)

1. Kahn S.E., and Porte Jr. D. Pathophysiology of type II diabetes mellitus. In: Porte Jr. D., and Sherwin R.S. (Eds). Diabetes Mellitus (1996), Appleton & Lange, Stamford, CT 487-512
2. Kahn S.E. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am. J. Med. 108 Suppl. 6a (2000) 2S-8S
3. Rudenski A.S., Hadden D.R., Atkinson A.B., Kennedy L., Matthews D.R., Merrett J.D., et al. Natural history of pancreatic islet beta-cell function in type 2 diabetes mellitus studies over six years by homeostasis model assessment. Diabetes Med. 5 (1988) 265-267
4. Lebovitz H.E. Insulin secretagogues: old and new. Diabetes Rev. 7 (1999) l39-l53
5. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., and Turner R.C. UKPDS 26 sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetes Med. 15 (1998) 297-303
6. Larsson H., Berglund G., and Ahren B. Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. J. Clin. Endocrinol. Metab. 80 (1995) 1778-1782
7. Pimenta W., Mitrakou A., Jensen T., Yki-Järvinen H., Daily G., and Gerich J. Insulin secretion and insulin sensitivity in people with impaired glucose tolerance. Diabetes Med. 13 (1996) S33-S36
8. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., and Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15 (1992) 193-203
9. Berkowitz K., Peters R., Kjos S.L., Goico J., Marroquin A., Dunn M.E., et al. Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. Diabetes 45 (1996) 1572-1579
10. Lister C.A., Moore G.B.T., Piercy V., Newman M., Chapman H., and Smith S.A. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content (Abstract). Diabetologia 42 Suppl. 1 (1999) A150
11. Bell D.S. Beta-cell rejuvenation with thiazolidinediones. Am. J. Med. 115 Suppl. 8A (2003) 20S-23S
12. Prigeon R.L., Kahn S.E., and Porte Jr. D. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 83 (1998) 3819-3823
13. World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus, Geneva, World Health Organization, 1999.
14. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237 (1979) E214-E223
15. Bergman R.N., Phillips L.S., and Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man. J. Clin. Invest. 68 (1981) 1456-1467
16. Tripathy D., Carlsson M., Almgren P., Isomaa B., Taskinen M.R., Tuomi T., et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia study. Diabetes 49 (2000) 975-980
17. Porte Jr. D., and Kahn S.E. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 50 Suppl. 1 (2001) 5160-5163
18. Clark A., Jones L.C., de Koning E., Hansen B.C., and Matthews D.R. Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function?. Diabetes 50 Suppl. 1 (2001) 5169-5171
19. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest. 104 (1999) 787-794
20. Herz M., Johns D., Reviriego J., Grossman L.D., Godin C., Duran S., et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther. 25 (2003) 1074-1095
21. Miyazaki Y., Matsuda M., and DeFronzo R.A. Dose-response effect on pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25 (2002) 517-523
22. Gerich J.E. Metabolic abnormalities in impaired glucose tolerance. Metabolism 46 (1997) 40-43
23. Yoneda H., Ikegami H., Yamamoto Y., Yamato E., Cha T., Kawaguchi Y., et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care 15 (1992) 1517-1521
24. Diamond M.P., Thornton K., Connoly-Diamond M., Sherwin R.S., and DeFronzo R.A. Reciprocal variation in insulin-mediated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance. J. Soc. Gynecol. Invest. 2 (1995) 708-715
25. Mitrakou A., Vuorinen-Markkola H., Raptis G., Toft I., Mokan M., Strumph P., et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp. J. Clin. Endocrinol. Metab. 75 (1992) 379-382
26. Rubenstein A.H., Clark J.L., Melani F., and Steiner D. Secretion of proinsulin C-peptide by pancreatic beta cells and its circulation in blood. Nature 224 (1969) 697-699
27. Porte Jr. D., and Kahn S.E. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet ß-cell dysfunction?. Diabetes 38 (1989) 1333-1336
28. Porte. Banting lecture 1990, ß-cells in type II diabetes mellitus. Diabetes 40 (1991) 166-180
29. Davies M.J., Rayman G., Gray I.P., Day J.L., and Hales C.N. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabetes Med. 10 (1993) 313-320
30. Krentz A.J., Clark P.M., Cox L., and Nattrass M. Hyperproinsulinemia in impaired glucose tolerance. Clin. Sci. 85 (1993) 97-100
31. Kahn S.E., and Halban P.A. Release of incompletely processed proinsulin is the cause of disproportionate proinsulinemia of NIDDM. Diabetes 46 (1997) 1725-1732
32. Kahn S.E., Leonetti D.L., Prigeon R.L., Boyko E.J., Bergstrom R.W., and Fujimoto W.Y. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44 (1995) 173-179
33. Haffner S.M., Gonzalez C., Mykkänen L., and Stern M. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study. Diabetologia 40 (1997) 830-837
34. Hanley A.J.G., D'Agostino Jr. R., Wagenknecht L.E., Saad M.F., Savage P.J., Bergman R., and Haffner S.M. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1263-1270
35. Zethelius B., Byberg L., Hales C.N., Lithell H., and Berne C. Proinsulin and acute insulin response independently predict type 2 diabetes mellitus in men, report from 27 years of follow-up study. Diabetologia 46 (2003) 20-26
36. Maggs D.G., Buchanan T.A., Burant C.F., Cline G., Gumbiner B., Hsueh W.A., et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus; a randomized, double-blind placebo-controlled trial. Ann. Intern. Med. 128 (1998) 176-185
37. Fias J.P., Yu J.G., Kruszynska Y.T., and Olefsky J.M. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 23 (2000) 64-69
38. Miyazaki Y., Mahankali A., Matsuda M., Glass L., Mahankali S., Ferrannini E., Cusi K., Mandarino L.J., and DeFronzo R.A. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
39. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., and Doddrell D.M. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obesity Res. 10 (2002) 1008-1015
40. Rosetti L., Giaccari A., and DeFronzo R.A. Glucose toxicity. Diabetes Care 13 (1990) 610-629
41. Leahy J.L., Bonner-Weir S., and Weir G.C. β-Cell dysfunction induced by chronic hyperglycemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15 (1992) 442-453
42. Vague P., and Moulin J.P. The defective glucose sensitivity of the β-cell in non insulin dependent diabetes. Improvement after twenty hours of normoglycaemia. Metab. Clin. Exp. 31 (1982) 139-142
43. Hidaka H., Nagulesparan M., Klimes I., Clark R., Sasaki H., Aronoff S.L., Vasquez B., Rubenstein A.H., and Unger R.H. Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics. J. Clin. Endocrinol. Metab. 54 (1985) 217-222
44. Unger R.H., and Zhou Y.T. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes 50 (2001) S118-S121
45. Kashyap S., Belfort R., Gastaldelli A., Pratipanawatr T., Berria R., Pratipanawater W., et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52 (2003) 2461-2474
46. Carpentier A., Mittelman S.D., Bergman R.N., Giacca A., and Lewis G.F. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic human but not in individuals with type 2 diabetes. Diabetes 49 (2000) 399-408
47. Shimabukuro M., Zhou Y.T., Lee Y., and Unger R.H. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273 (1998) 3547-3550